Orthofix adds scorn to Ramius nominees
This article was originally published in Clinica
Orthopaedics specialist Orthofix International has again raised concerns about the suitability of a potential board member nominated by its disgruntled shareholder Ramius. Orthofix (McKinney, Texas) questioned the nomination of Steven Lee, calling his tenure as president, CEO and chairman of diabetes supplies and service firm PolyMedica into dispute. While Mr Lee was at PolyMedica, the firm was embroiled in two whistleblower lawsuits alleging that the company was involved in fraud and improper reimbursement billing (see Clinica No 1025, p 12). This is the second of Ramius’ board nominations to be criticised by Orthofix – last week the company condemned the nomination of Peter Feld. However, Orthofix did say that it was willing to meet and interview the remaining two board nominees Charles Orsatti and J Michael Egan.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals